Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glycogen Storage Disease Type II | 16 | 2022 | 20 | 7.730 |
Why?
|
| Respiratory Insufficiency | 6 | 2022 | 95 | 3.250 |
Why?
|
| alpha-Glucosidases | 7 | 2022 | 15 | 2.580 |
Why?
|
| Genetic Therapy | 11 | 2022 | 586 | 2.160 |
Why?
|
| Hypoglossal Nerve | 4 | 2020 | 4 | 2.060 |
Why?
|
| Motor Neurons | 5 | 2020 | 185 | 1.810 |
Why?
|
| Dependovirus | 12 | 2022 | 541 | 1.800 |
Why?
|
| Spinocerebellar Ataxias | 2 | 2022 | 11 | 1.790 |
Why?
|
| Muscular Dystrophy, Duchenne | 2 | 2022 | 20 | 1.690 |
Why?
|
| Lung Diseases | 3 | 2017 | 126 | 1.660 |
Why?
|
| Neuromuscular Diseases | 2 | 2022 | 16 | 1.560 |
Why?
|
| Respiration | 3 | 2022 | 77 | 1.530 |
Why?
|
| Amyotrophic Lateral Sclerosis | 6 | 2020 | 435 | 1.480 |
Why?
|
| Phrenic Nerve | 5 | 2020 | 5 | 1.430 |
Why?
|
| Disease Models, Animal | 14 | 2022 | 1781 | 1.410 |
Why?
|
| Genetic Vectors | 9 | 2022 | 665 | 1.340 |
Why?
|
| Gene Transfer Techniques | 3 | 2018 | 263 | 1.080 |
Why?
|
| Enzyme Replacement Therapy | 4 | 2021 | 11 | 1.070 |
Why?
|
| Dystrophin | 2 | 2022 | 20 | 1.020 |
Why?
|
| Mice | 20 | 2022 | 9076 | 0.970 |
Why?
|
| Animals | 28 | 2022 | 17697 | 0.960 |
Why?
|
| Glycogen | 7 | 2022 | 37 | 0.960 |
Why?
|
| Muscle, Skeletal | 6 | 2022 | 578 | 0.950 |
Why?
|
| Neurology | 1 | 2022 | 24 | 0.940 |
Why?
|
| Deglutition Disorders | 1 | 2022 | 32 | 0.930 |
Why?
|
| Muscle, Smooth | 3 | 2021 | 84 | 0.890 |
Why?
|
| Retinal Degeneration | 1 | 2021 | 25 | 0.850 |
Why?
|
| Superoxide Dismutase | 3 | 2017 | 201 | 0.830 |
Why?
|
| Loss of Function Mutation | 1 | 2020 | 18 | 0.800 |
Why?
|
| Nerve Degeneration | 1 | 2020 | 60 | 0.780 |
Why?
|
| Membrane Transport Proteins | 1 | 2020 | 108 | 0.770 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2017 | 48 | 0.770 |
Why?
|
| Axons | 1 | 2020 | 115 | 0.760 |
Why?
|
| Acyl-CoA Dehydrogenase, Long-Chain | 1 | 2019 | 10 | 0.750 |
Why?
|
| Lipid Metabolism, Inborn Errors | 1 | 2019 | 12 | 0.740 |
Why?
|
| Macroglossia | 1 | 2019 | 1 | 0.740 |
Why?
|
| Mitochondrial Diseases | 1 | 2019 | 20 | 0.730 |
Why?
|
| Muscular Diseases | 1 | 2019 | 38 | 0.730 |
Why?
|
| Motor Neuron Disease | 1 | 2019 | 28 | 0.720 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 358 | 0.670 |
Why?
|
| Mice, Knockout | 8 | 2022 | 1871 | 0.650 |
Why?
|
| Craniofacial Abnormalities | 1 | 2017 | 23 | 0.650 |
Why?
|
| Phenotype | 2 | 2020 | 993 | 0.650 |
Why?
|
| Infant, Premature, Diseases | 1 | 2017 | 46 | 0.630 |
Why?
|
| Down Syndrome | 1 | 2017 | 42 | 0.620 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2017 | 50 | 0.590 |
Why?
|
| Long-Term Potentiation | 1 | 2015 | 20 | 0.580 |
Why?
|
| Respiratory System Agents | 1 | 2015 | 3 | 0.580 |
Why?
|
| Isoxazoles | 1 | 2015 | 13 | 0.580 |
Why?
|
| Hypoxia | 1 | 2015 | 73 | 0.560 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2015 | 60 | 0.540 |
Why?
|
| Humans | 27 | 2022 | 49598 | 0.530 |
Why?
|
| Lung | 2 | 2018 | 606 | 0.520 |
Why?
|
| Referral and Consultation | 1 | 2015 | 355 | 0.440 |
Why?
|
| Inhalation Spacers | 1 | 2011 | 1 | 0.440 |
Why?
|
| Gene Targeting | 1 | 2012 | 81 | 0.440 |
Why?
|
| Parents | 1 | 2015 | 311 | 0.440 |
Why?
|
| Androstadienes | 1 | 2011 | 14 | 0.440 |
Why?
|
| Respiratory Function Tests | 3 | 2020 | 89 | 0.430 |
Why?
|
| Fontan Procedure | 1 | 2011 | 3 | 0.430 |
Why?
|
| Bronchitis | 1 | 2011 | 23 | 0.420 |
Why?
|
| Child | 7 | 2020 | 3783 | 0.420 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2011 | 38 | 0.420 |
Why?
|
| Heart Transplantation | 1 | 2011 | 67 | 0.400 |
Why?
|
| Smoking | 1 | 2015 | 741 | 0.390 |
Why?
|
| Smoking Cessation | 1 | 2015 | 557 | 0.380 |
Why?
|
| Child, Preschool | 4 | 2020 | 1706 | 0.320 |
Why?
|
| Gene Expression | 2 | 2019 | 753 | 0.280 |
Why?
|
| Superoxide Dismutase-1 | 3 | 2020 | 128 | 0.270 |
Why?
|
| Diaphragm | 3 | 2020 | 18 | 0.260 |
Why?
|
| Treatment Outcome | 4 | 2020 | 3887 | 0.260 |
Why?
|
| Respiratory Muscles | 2 | 2013 | 4 | 0.250 |
Why?
|
| Transduction, Genetic | 3 | 2022 | 203 | 0.240 |
Why?
|
| Dysarthria | 1 | 2022 | 9 | 0.240 |
Why?
|
| Asthma | 2 | 2017 | 369 | 0.230 |
Why?
|
| Infant | 2 | 2017 | 1387 | 0.220 |
Why?
|
| Male | 7 | 2020 | 23121 | 0.220 |
Why?
|
| Ataxin-7 | 1 | 2021 | 1 | 0.220 |
Why?
|
| MicroRNAs | 2 | 2020 | 646 | 0.210 |
Why?
|
| Methacholine Chloride | 2 | 2021 | 29 | 0.210 |
Why?
|
| Hemiplegia | 1 | 2021 | 3 | 0.210 |
Why?
|
| Adolescent | 3 | 2020 | 5317 | 0.210 |
Why?
|
| Muscle Relaxation | 1 | 2021 | 23 | 0.210 |
Why?
|
| Taste | 1 | 2021 | 25 | 0.210 |
Why?
|
| Mice, Inbred mdx | 1 | 2020 | 8 | 0.200 |
Why?
|
| Deglutition | 1 | 2020 | 13 | 0.200 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2021 | 108 | 0.200 |
Why?
|
| Muscle Contraction | 2 | 2021 | 160 | 0.190 |
Why?
|
| Female | 7 | 2020 | 26314 | 0.190 |
Why?
|
| Carnitine | 1 | 2019 | 17 | 0.190 |
Why?
|
| Gene Deletion | 1 | 2021 | 296 | 0.190 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 2854 | 0.180 |
Why?
|
| Mice, 129 Strain | 2 | 2016 | 36 | 0.180 |
Why?
|
| Gene Editing | 1 | 2022 | 237 | 0.180 |
Why?
|
| Survivors | 1 | 2020 | 139 | 0.180 |
Why?
|
| Nerve Tissue Proteins | 1 | 2021 | 393 | 0.170 |
Why?
|
| Young Adult | 2 | 2020 | 3698 | 0.170 |
Why?
|
| Spinal Cord | 2 | 2016 | 132 | 0.170 |
Why?
|
| Pulmonary Emphysema | 1 | 2018 | 24 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 2 | 2015 | 602 | 0.170 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 1114 | 0.170 |
Why?
|
| Enzyme Activation | 1 | 2018 | 327 | 0.160 |
Why?
|
| Liver | 2 | 2019 | 709 | 0.160 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 189 | 0.160 |
Why?
|
| Potassium Chloride | 1 | 2017 | 16 | 0.160 |
Why?
|
| Albuterol | 1 | 2017 | 17 | 0.160 |
Why?
|
| Extracellular Space | 1 | 2017 | 28 | 0.160 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2018 | 82 | 0.160 |
Why?
|
| Trachea | 1 | 2017 | 67 | 0.160 |
Why?
|
| Bronchi | 1 | 2017 | 66 | 0.160 |
Why?
|
| Neuromuscular Junction | 2 | 2014 | 87 | 0.160 |
Why?
|
| Quality of Life | 1 | 2022 | 736 | 0.150 |
Why?
|
| Mice, Mutant Strains | 1 | 2017 | 294 | 0.150 |
Why?
|
| Medulla Oblongata | 1 | 2016 | 8 | 0.150 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 811 | 0.150 |
Why?
|
| Synaptic Potentials | 1 | 2015 | 7 | 0.150 |
Why?
|
| Infant, Premature | 1 | 2017 | 155 | 0.150 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2016 | 74 | 0.140 |
Why?
|
| Calcium Signaling | 1 | 2017 | 150 | 0.140 |
Why?
|
| Brain Stem | 1 | 2015 | 29 | 0.140 |
Why?
|
| Florida | 1 | 2015 | 27 | 0.140 |
Why?
|
| Hotlines | 1 | 2015 | 16 | 0.140 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 81 | 0.140 |
Why?
|
| Intention | 1 | 2015 | 54 | 0.140 |
Why?
|
| Prognosis | 1 | 2018 | 1250 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 96 | 0.130 |
Why?
|
| Cystic Fibrosis | 1 | 2015 | 105 | 0.130 |
Why?
|
| Myofibrils | 1 | 2013 | 16 | 0.130 |
Why?
|
| Injections, Intramuscular | 1 | 2013 | 67 | 0.130 |
Why?
|
| Infant, Newborn | 1 | 2017 | 1161 | 0.120 |
Why?
|
| Caregivers | 1 | 2015 | 157 | 0.120 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 117 | 0.120 |
Why?
|
| Motor Activity | 1 | 2015 | 321 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2015 | 671 | 0.110 |
Why?
|
| Metered Dose Inhalers | 1 | 2011 | 7 | 0.110 |
Why?
|
| Adult | 2 | 2020 | 13325 | 0.110 |
Why?
|
| Fluticasone | 1 | 2011 | 5 | 0.110 |
Why?
|
| Risk Factors | 2 | 2017 | 4246 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 187 | 0.110 |
Why?
|
| Sputum | 1 | 2011 | 23 | 0.110 |
Why?
|
| Azithromycin | 1 | 2011 | 17 | 0.110 |
Why?
|
| Heart | 1 | 2013 | 214 | 0.110 |
Why?
|
| Chromatography, Liquid | 1 | 2011 | 105 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2014 | 587 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 620 | 0.100 |
Why?
|
| Heart Defects, Congenital | 1 | 2011 | 58 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 1 | 2012 | 372 | 0.100 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 259 | 0.100 |
Why?
|
| Cough | 1 | 2011 | 160 | 0.090 |
Why?
|
| Macaca | 1 | 2022 | 22 | 0.060 |
Why?
|
| Swine | 1 | 2022 | 294 | 0.050 |
Why?
|
| Tongue | 1 | 2021 | 15 | 0.050 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2021 | 27 | 0.050 |
Why?
|
| Respiratory System | 1 | 2021 | 36 | 0.050 |
Why?
|
| Mutation | 2 | 2021 | 2187 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2020 | 87 | 0.050 |
Why?
|
| Ligands | 1 | 2021 | 380 | 0.050 |
Why?
|
| Middle Aged | 1 | 2015 | 13448 | 0.050 |
Why?
|
| Base Sequence | 1 | 2021 | 1251 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 684 | 0.040 |
Why?
|
| Injections, Intraventricular | 1 | 2016 | 15 | 0.040 |
Why?
|
| Lateral Ventricles | 1 | 2016 | 5 | 0.040 |
Why?
|
| Neuroimmunomodulation | 1 | 2016 | 7 | 0.040 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2016 | 29 | 0.040 |
Why?
|
| Thoracic Vertebrae | 1 | 2016 | 25 | 0.040 |
Why?
|
| Respiratory Mucosa | 1 | 2016 | 37 | 0.040 |
Why?
|
| Cervical Vertebrae | 1 | 2016 | 38 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2016 | 76 | 0.040 |
Why?
|
| Biomarkers | 1 | 2020 | 1002 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 2016 | 228 | 0.040 |
Why?
|
| Caspase 3 | 1 | 2016 | 91 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 118 | 0.030 |
Why?
|
| Pediatrics | 1 | 2017 | 249 | 0.030 |
Why?
|
| Tibia | 1 | 2014 | 39 | 0.030 |
Why?
|
| DNA Damage | 1 | 2016 | 271 | 0.030 |
Why?
|
| Pleura | 1 | 2013 | 10 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 354 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1142 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 718 | 0.030 |
Why?
|
| Random Allocation | 1 | 2013 | 193 | 0.030 |
Why?
|
| Myocardium | 1 | 2013 | 189 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2016 | 588 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2016 | 2064 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 979 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2020 | 4513 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 378 | 0.020 |
Why?
|